期刊文献+

9-芴酮的简易还原氨化 被引量:1

On Facile Reductive Amination of 9-Fluorenone
下载PDF
导出
摘要 9-芴基结构单元是重要的多功能中间体和生物活性片段,9-芴基的官能化在药物分子转换方面具有重要意义.报道了9-芴酮还原氨化的实用方法.9-芴酮与盐酸羟胺反应得9-芴酮肟,9-芴酮肟经多种还原剂还原为9-芴胺.通过条件优化,高收率(高于95%)得到9-芴肟,中等收率(锌粉还原法)制得9-芴胺,从而发现了未见文献报道的9-芴酮肟及9-芴胺合成的简便操作方法. 9-Fluorenyl structural unit is fundamental intermediates and essential biologically active frag-ment ,and the functionalization of 9-Fluorenyl is crucial in the drug molecule conversion .Herein a practical method of reductive amination of 9-fluorenone has been reported in this paper .A high yield conversion (〉95% ) has been achieved from 9-fluorenone to 9-fluorenone oxime under optimal condition ;furthermore , 9H-Fluoren-9-amine has been obtained by Zn reduction process with a medium yield for the first time , which is much better than reported in literature .This novel method provides a useful synthetic procedure with simple operation and low cost ,which also exhibits high commercial value .
出处 《西南师范大学学报(自然科学版)》 CAS CSCD 北大核心 2014年第9期26-29,共4页 Journal of Southwest China Normal University(Natural Science Edition)
基金 国家级大学生创新训练项目(201310635036)
关键词 9-芴酮 9-芴酮肟 9-芴胺 还原氨化 9-Fluorenone 9-Fluorenone oxime 9H-Fluoren-9-amine Reductive Amination
  • 相关文献

参考文献15

  • 1MOHLERML, HE YL, WUZZ, etat. Recent and EmergingAntidlabetesTargets[J]. MedResRev, 2009: 29(1): 125- 195.
  • 2KRENTZ A J, BAILEY C J. Oral Antidiabetic Agents Current Rolein Type2 Diabetes MelIitus [J]. Drugs,2005, 65(3): 385-411.
  • 3杨大成,顾雪元,奉萍.对氨基苯甲酸乙酯与苯乙酮和芳香醛的Mannich反应[J].西南师范大学学报(自然科学版),1997,22(1):54-57. 被引量:11
  • 4熊阳,夏科学,杨龙,李晟,田会会,杨大成.对氨基苯甲酸烷基酯的简易合成[J].西南大学学报(自然科学版),2013,35(9):74-79. 被引量:5
  • 5BACON E R, C HATTERJEE S, DUNN D, et aI, Preparation of Trieyclic Aromatic and Bisphenyt Sulfinyl Derivatives for the Treatment of Excessive Sleepiness [P]. U S Pat Appl Publ, 2005, US 2005023404 0 At 20051020.
  • 6MAILLIET P, BERTIN L, GUYON T, et al. New Azabenzimidazolyl and BenzimidazoiyI Fluorene Derivatives, Compo- sitions Containing Them and Their Use for Treating Cancer [P]. PCT Int Appl, 2006, WO 2006/123061 A2.
  • 7GUSTAVE B, VIVIAN B, JON C, et al. Compositions and Methods for Inhibiting Fungal Growth [P]. U S Pat, 2002, US 6423519 B1.
  • 8蒋华良,李剑,来鲁华,等.取代苯甲酰脲类化合物及其制备方法和用途[P].国际公布号:WO2010/127558A1.
  • 9LAVOIE E J, TULLEY F L, BEDENKO V, et ai. Comparative Studies on the Tumor Initiating Activity and Metabo- lism of MethylfIuorenes and Methytbenzofluorenes [J]. Chem Anal b- BioI, I98I, 5: 417- 427.
  • 10WANG Hang, YAN Ju-fang, FAN Li, et al, Synthesis and Antidiabetic Performance of β-Amino Ketone ContainingNabumetoneMoiety[J].BioorgMedChem,2012,20:2119-2t30.

二级参考文献101

  • 1冯君,郭彦伸,陆颖,郭宗儒.PPAR激动剂的定向设计、虚拟筛选及合成[J].化学学报,2004,62(16):1544-1550. 被引量:14
  • 2陈旭东,王新波,范莉,杨大成.CdS纳米晶与多肽相互作用研究[J].化学学报,2005,63(17):1600-1606. 被引量:21
  • 3刘艳辉,刘素琴,毛卿.氨基磺酸催化合成苯甲酸乙酯[J].湖南理工学院学报(自然科学版),2005,18(4):56-58. 被引量:7
  • 4张灏,严梅荣,彭冬梅.麦芽糖脂肪酸酯的制备研究[J].食品科学,2006,27(11):257-259. 被引量:7
  • 5杨大成,顾雪元,奉萍.对氨基苯甲酸乙酯与苯乙酮和芳香醛的Mannich反应[J].西南师范大学学报(自然科学版),1997,22(1):54-57. 被引量:11
  • 6Yang WY, Lu JM, Weng JP, Jia WP, Ji LN, Xiao JZ, Shan ZY, Liu J, Tian HM, Ji QH, Zhu DL, Ge JP, Lin LX, Chen L, Guo XH, Zhao ZG, Li Q, Zhou ZG, Shan GL, He J. Prevalence of diabetes among men and women in China. New Engl J Med, 2010, 362:1090-1101.
  • 7Coutts SJ, Kelly TA, Snow RJ, Kennedy CA, Barton RW, Adams J, Krolikowski DA, Freeman DM, Campbell SJ, Ksiazek JF, Bachovchin WW. Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides. J Med Chern, 1996, 39:2087-2094.
  • 8Bell GI, Santerre RF, Mullenhach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature, 1983, 302:716-718.
  • 9Huttunen KM, Mannila A, Laine K, Kemppainen E, Leppanen J, Vepsalainen J, Jarvinen T, Rautio J. The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption. J Med Chem, 2009, 52:4142-4148.
  • 10Eckhardt M, Langkopf E, Mark M, Tadayyon M, Thomas L, Nar H, Pfrengle W, Guth B, Lotz R, Sieger P, Fuchs H, Himmelsbach F. 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione(BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem, 2007, 50: 6450-6453.

共引文献39

同被引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部